Literature DB >> 9330990

Strategies for improving the postmortem neuropathological diagnosis of Alzheimer's disease.

J Q Trojanowski1, C M Clark, M L Schmidt, S E Arnold, V M Lee.   

Abstract

Despite recognition that Alzheimer's disease (AD) is a polygenic and heterogeneous dementing neurodegenerative disorder, there is continued merit in defining the AD phenotype by the presence of progressive cognitive impairments and the pathological brain lesions (senile plaques, neurofibrillary tangles) as originally formulated by Alois Alzheimer. This position paper discusses the rationale for emphasizing the detection of both beta amyloid-rich plaques and tau-rich tangles in the next iteration of the neuropathological criteria for the postmortem diagnosis of AD that has been recommended by the Working Group on Consensus Criteria for the Postmortem Diagnosis of AD. Further, it also underlines the need to exploit continuing advances in understanding the pathobiology of plaques and tangles in subsequent iterations of these criteria. It is expected that such efforts, now and in the future, will hasten the development of strategies for the early and accurate antemortem diagnosis of AD as well as the discovery of effective treatments for this common dementing illness of the elderly.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9330990     DOI: 10.1016/s0197-4580(97)00075-4

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  6 in total

1.  Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia.

Authors:  Young Kyoung Jang; Chul Hyoung Lyoo; Seongbeom Park; Seung Jun Oh; Hanna Cho; Minyoung Oh; Young Hoon Ryu; Jae Yong Choi; Gil D Rabinovici; Hee Jin Kim; Seung Hwan Moon; Hyemin Jang; Jin San Lee; William J Jagust; Duk L Na; Jae Seung Kim; Sang Won Seo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-16       Impact factor: 9.236

Review 2.  Positron emission tomography radioligands for in vivo imaging of Aβ plaques.

Authors:  N Scott Mason; Chester A Mathis; William E Klunk
Journal:  J Labelled Comp Radiopharm       Date:  2013 Mar-Apr       Impact factor: 1.921

3.  Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease.

Authors:  Miles C Miller; Rosemarie Tavares; Conrad E Johanson; Virginia Hovanesian; John E Donahue; Liliana Gonzalez; Gerald D Silverberg; Edward G Stopa
Journal:  Brain Res       Date:  2008-07-14       Impact factor: 3.252

4.  The 21st century epidemic: infections as inductors of neuro-degeneration associated with Alzheimer's Disease.

Authors:  Federico Licastro; Ilaria Carbone; Elena Raschi; Elisa Porcellini
Journal:  Immun Ageing       Date:  2014-12-05       Impact factor: 6.400

5.  Persistent infections, immune-senescence and Alzheimer's disease.

Authors:  Federico Licastro; Elisa Porcellini
Journal:  Oncoscience       Date:  2016-06-30

Review 6.  PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape.

Authors:  Bright Chukwunwike Uzuegbunam; Damiano Librizzi; Behrooz Hooshyar Yousefi
Journal:  Molecules       Date:  2020-02-21       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.